1-sec-butyl-4-methyl-piperazine | 58910-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-sec-butyl-4-methyl-piperazine
• 英文别名: N-methyl-N-[3... butyl]piperazine；Piperazine, 1-methyl-4-(1-methylpropyl)-(9CI)；1-butan-2-yl-4-methylpiperazine
• CAS: 58910-33-1
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: UOPPHGCAWSUIAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-甲基哌嗪 、 新柠檬醛; 3-(4-甲基-3-环己烯基)丁醛; beta,4-二甲基-3-环己烯-1-丙醛 、 1-sec-butyl-4-methyl-piperazine 生成 N-Methyl-N-<3-(4-methyl-3-cyclohexenyl)butyl>piperazin
  参考文献：
  名称：

  N-[3-(4-Methyl-3-cyclohexenyl)butyl]amines and their use as plant growth

  摘要：

  N-[3-(4-甲基-3-环己烯基)丁基]胺是一种在植物生长调节中高效的新化合物。

  公开号：

  US04030908A1

文献信息

• PROCESS FOR SYNTHESIZING CARBAPENEM USING RANEY NICKEL
  申请人：MANCA Antonio

  公开号：US20100004463A1

  公开（公告）日：2010-01-07

  Convenient method for obtaining carbapenem by hydrogenation with Raney Nickel, as an alternative to the known catalytic hydrogenation conducted under hydrogen overpressure in the presence of Palladium, starting from corresponding protected intermediates such as p-nitrobenzylesters and with optional suitable protections of any primary and secondary amino functions structurally present.

  使用Raney镍进行氢化是一种获取碳青霉烯的便捷方法，作为已知的在钯存在下，在高压氢气中进行催化氢化的替代方法，从相应的保护中间体如对硝基苄酯开始，并可选择性地保护任何结构上存在的一级和二级氨基功能。
• NOVEL COMPOUNDS
  申请人：Buttar David

  公开号：US20080153812A1

  公开（公告）日：2008-06-26

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一个式(I)的化合物，或其药用可接受的盐。还提供了制备式1化合物的方法，以及将式1化合物用作药物和用于癌症治疗的用途。
• Aza-Substituted Spiro Derivatives
  申请人：Jitsuoka Makoto

  公开号：US20090258871A1

  公开（公告）日：2009-10-15

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）的化合物或其药学上可接受的盐：[其中X、Y、Z和W各自独立地表示甲基基团或氮原子，前提是当X、Y、Z和W全部为甲基基团时；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示甲基基团或氮原子；R表示由以下式子（II-1）表示的基团（其中R6、R7和R8各自独立地表示较低的烷基基团或类似物）。
• Carbamoyl-Substituted Spiro Derivative
  申请人：Jitsuoka Makoto

  公开号：US20080171753A1

  公开（公告）日：2008-07-17

  A compound represented by, e.g. the formula (I): [wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent —C(O)—, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.; (wherein R 6 represents a lower alkyl, etc; and R 7 and R 8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.

  化合物的化学式为(I):[其中X、Y、Z和W各自独立地表示可选择性取代的甲烷基；A、B和D各自独立地表示—C(O)—等；Q表示甲烷基或氮；R表示化学式(II-1)，可选择性地取代较低的烷基等；(其中R6表示较低的烷基等；R7和R8各自独立地表示较低的烷基等)]或其药学上可接受的盐。这些化合物和盐对组胺H3受体具有拮抗活性或反向激动活性。它们可用于预防或治疗代谢性疾病、循环系统疾病或神经疾病。
• AZA-SUBSTITUTED SPIRO DERIVATIVES
  申请人：Jitsuoka Makoto

  公开号：US20120149703A1

  公开（公告）日：2012-06-14

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）或其药学上可接受的盐的化合物： 其中X、Y、Z和W各自独立地表示一个甲基基团或氮原子，前提是X、Y、Z和W全部都是甲基基团的情况除外；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示一个甲基基团或氮原子；R表示以下式子（II-1）所表示的基团（其中R6、R7和R8各自独立地表示低级烷基或类似物）。